NEW YORK, July 15, 2010 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment and prevention of Alzheimer’s disease, today announced that it is pleased with the data presented on Bapineuzumab and Ponezumab (PF-04360365) at the Alzheimer’s Association International Conference (ICAD), taking place in Honolulu, HI from July 10-15.
